-
Tiantan Biological to Acquire Wuhan Zhongyuan Ruide for $185 Million, Expanding Plasma Resources
•
BEIJING—Beijing Tiantan Biological Products Co., Ltd (Tiantan Biological, SHA: 600161) has announced that its subsidiary, Chengdu Rongsheng Pharmaceutical Co., Ltd (Chengdu Rongsheng), intends to acquire 100% equity interest in Wuhan Zhongyuan Ruide Biological Products Co., Ltd (Zhongyuan Ruide), a wholly-owned subsidiary of CSL Behring Asia Pacific Limited (CSL Asia Pacific),…
-
Beijing Tiantan Biological Halts Phase III Clinical Trial for CMV Immunoglobulin Citing Strategic Reasons
•
Beijing Tiantan Biological Products Co., Ltd (SHA: 600161), a biopharmaceutical firm based in China, has declared its decision to discontinue a Phase III clinical study for its intravenous injection of cytomegalovirus human immunoglobulin (pH4). The company cited prevailing market conditions and internal strategic planning as the key factors influencing this…
